PriceTargets.com logo

Azitra - AZTR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 992.90%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.37 As of 12/4/2025 05:10 PM ET
▼ -0.0051 (-1.37%)

This chart shows the closing price for AZTR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Azitra Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AZTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AZTR

Analyst Price Target is $4.00
▲ +992.90% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Azitra in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 992.90% upside from the last price of $0.37.

This chart shows the closing price for AZTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Azitra.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/24/2025Maxim GroupLower TargetBuy ➝ Buy$13.32 ➝ $4.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Azitra logo
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Read More

Today's Range

Now: $0.37
Low: $0.35
High: $0.38

50 Day Range

MA: $0.52
Low: $0.31
High: $0.79

52 Week Range

Now: $0.37
Low: $0.30
High: $4.33

Volume

172,100 shs

Average Volume

626,183 shs

Market Capitalization

$3.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Azitra?

The following Wall Street analysts have issued stock ratings on Azitra in the last year: Maxim Group.
View the latest analyst ratings for AZTR.

What is the current price target for Azitra?

0 Wall Street analysts have set twelve-month price targets for Azitra in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 992.9%. Maxim Group has the highest price target set, predicting AZTR will reach $4.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $4.00 for Azitra in the next year.
View the latest price targets for AZTR.

What is the current consensus analyst rating for Azitra?

Azitra currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AZTR will outperform the market and that investors should add to their positions of Azitra.
View the latest ratings for AZTR.

What other companies compete with Azitra?

Other companies that are similar to Azitra include Novelion Therapeutics, Tempest Therapeutics, Longeveron, Phio Pharmaceuticals and Curanex Pharmaceuticals. Learn More about companies similar to Azitra.

How do I contact Azitra's investor relations team?

Azitra's physical mailing address is 21 Business Park Drive, Branford, CT 06405, United States. The company's listed phone number is 203-646-6446. The official website for Azitra is azitrainc.com. Learn More about contacing Azitra investor relations.